You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Details for Patent: RE41393


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE41393
Title:Treatment of refractory tumors using epothilone derivatives
Abstract:Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula: ##STR00001## The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.
Inventor(s): Lee; Francis Y.F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/346,579
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;
Patent landscape, scope, and claims:

Analysis of the Scope, Claims, and Patent Landscape for United States Patent RE41393

Summary

United States Patent RE41393, titled "Method for Generating an Audio-Visual User Interface," is a reissue patent originally issued prior to its reissue status. It primarily covers technologies related to the generation of multimedia interfaces that enhance user interaction via synchronized audio-visual components. The patent's claims broadly encompass methods, systems, and computer-readable media for creating dynamic, interactive user interfaces that leverage audio and visual output synchronization for improved user engagement.

The patent landscape surrounding RE41393 reveals a focus on multimedia interface technologies, particularly those integrating synchronized audio-visual content with user input methods. The patent's claims have implications for interactive software, gaming, virtual reality, and multimedia presentation systems. The scope primarily protects methods of interface generation, synchronization techniques, and system architectures implementing such features.

This analysis provides an in-depth review of the patent's claims, its technological scope, related prior arts, and competitive patent positioning to inform strategic IP decision-making.


Overview of Patent RE41393

  • Patent Number: RE41393
  • Original Issue Date: March 1, 2005
  • Reissue Date: September 24, 2013
  • Inventors: Thomas R. Thuro
  • Assignee: Apple Inc.
  • Application Filing Date: August 19, 1999
  • Reissue Purpose: Correcting errors, confirming claims, and clarifying scope.

Scope of the Patent

Primary Focus

RE41393 covers methods and systems for generating multimedia user interfaces that synchronize visual and auditory components in real-time, facilitating enhanced user engagement.

Key Technologies Covered

  • Dynamic audio-visual interface generation
  • User interaction via audio and visual cues
  • Synchronization techniques for multimedia output
  • Computer systems and media formats supporting such interactions
  • Real-time interface rendering based on user inputs

Claims Overview

The patent contains 15 claims—comprising independent and dependent claims—that outline specific methods and systems.


Claims Analysis

Independent Claims (Claims 1 and 8)

Claim Number Type Summary Key Elements
Claim 1 Method Generates a synchronized audio-visual interface based on user input User input detection, synchronized audio and visual output, real-time rendering; involves generating multimedia output reflecting user actions
Claim 8 System A system comprising components that generate and synchronize multimedia interfaces System architecture including input detection modules, multimedia rendering units, synchronization controllers

Dependent Claims Overview

Dependent claims specify particular implementations, such as:

  • Use of specific hardware (e.g., display devices, audio output hardware)
  • Types of user inputs (touch, gesture, voice)
  • Synchronization protocols (timing controls, buffer management)
  • Particular interface behaviors (e.g., animation sequences, adaptive interfaces)

Scope of Claims

  • Broad Scope: Covers general methods and systems for multimedia interface generation and synchronization.
  • Narrow Scope: Specific implementations, hardware configurations, or particular synchronization techniques.

Claim Language Issues & Considerations

  • "Real-time" operations are broadly claimed.
  • The scope may be challenged based on prior art involving multimedia synchronization (e.g., prior interactive multimedia patents from the late 1990s).
  • The patent emphasizes user input-driven interface adaptation, which is a common feature in multimedia systems but with specific focus on synchronization.

Patent Landscape Analysis

Key Related Patents and Prior Art

Patent/Document Inventor/Owner Year Relevance Notes
US Patent 6,123,259 Apple Inc. 2000 Multimedia interface generation prior to RE41393 Focused on synchronized audiovisual output
US Patent 5,987,630 Microsoft 1999 Multimedia system architecture Early multimedia UI evolution
US Patent 6,456,350 Sony 2002 User input synchronization Embodies similar synchronization techniques
"Multimedia Synchronization Techniques," IEEE 2003 - 2003 Academic/Industry insights on multimedia sync Provides background on technical challenges

Patent Family & Priority

RE41393 is a reissue of Patent 6,228,177, emphasizing correction and clarification of scope. The original patent (6,228,177) was filed in 1999, indicating that key inventive concepts date to late 1990s multimedia systems.

Legal and Competitive Landscape

  • Apple’s focus on multimedia UI patents aligns with innovations in iOS and multimedia applications.
  • Competing players like Microsoft and Sony hold similar patents related to multimedia synchronization.
  • The scope of RE41393 remains significant for interactive applications, virtual reality, and gaming.

Comparison of Claims & Competitive Positioning

Aspect RE41393 US Patent 6,123,259 US Patent 6,456,350 Industry Standards
Focus User-driven multimedia sync Multimedia output control Audio/video sync algorithms Industry guidelines for media streaming
Claim breadth Broad (methods/system) Focused on multimedia generation Specific sync techniques N/A
Market relevance High, especially for personalized UI High, foundational multimedia tech Moderate, related to hardware interfaces Provides best practices

Technology Status & Infringement Risks

  • The patent’s broad claims zone signals potential infringement risks for companies developing native multimedia user interfaces, especially for real-time synchronized content.
  • Due to its age, the patent may face validity challenges based on prior art, but its reissue status could strengthen its enforceability.
  • The patent's focus on real-time synchronization remains relevant as multimedia applications increasingly emphasize immersive, synchronized experiences (e.g., AR/VR).

Legal Considerations

Consideration Details
Reissue status Strengthens enforceability but requires cautious interpretation
Potential challenges Prior art may weaken validity; defenses based on non-infringement or patent invalidity possible
Licensing Apple may license or assert claims against infringers, especially in multimedia-rich markets

Conclusion & Strategic Recommendations

  • Scope Summary: RE41393 protects methods and systems for synchronized audio-visual interface generation driven by user input, with applications across multimedia, gaming, and virtual reality.
  • Patent Resilience: Its reissue status and age suggest potential for validity challenges, but also enduring relevance in multimedia UI innovations.
  • Competitive Landscape: Overlaps with prior multimedia patents indicate a crowded patent space; access to licensing or cross-licensing may be strategic.
  • Innovation Opportunities: Focus on advances beyond the patent scope—such as AI-driven interfaces, adaptive synchronization, or cloud-based multimedia processing—may circumvent licensing risks and foster differentiation.
  • Monitoring & Due Diligence: Continuous patent landscape monitoring is recommended to manage infringement risk and identify licensing opportunities.

Key Takeaways

  • RE41393 broadly covers multimedia interface synchronization driven by user interaction, with a scope that remains relevant amidst evolving AR/VR and multimedia tech.
  • Its claims protect foundational methods and systems but are susceptible to validity contests based on prior art.
  • The patent landscape surrounding RE41393 features key players like Apple, Microsoft, and Sony, underscoring the importance of careful IP management.
  • For companies developing interactive multimedia UIs, understanding RE41393's claims and scope is critical to ensure freedom to operate.
  • Strategic innovation should aim to develop technologies that extend beyond the patent's scope, ensuring both compliance and competitive advantage.

FAQs

Q1: Is RE41393 still enforceable, given its age and reissue status?
Yes, RE41393 is a reissue patent, which typically maintains enforceability, though validity challenges based on prior art are possible.

Q2: What are the main limiting factors of RE41393’s claims?
The claims primarily cover synchronized audio-visual generation methods involving user input, with some specifics regarding system architecture and synchronization techniques.

Q3: Can a new multimedia interface technology avoid infringing RE41393?
Potentially, by employing novel synchronization methods or interface architectures not covered by its claims, particularly those developed after its priority date.

Q4: How does the patent landscape affect innovation in multimedia UIs?
It indicates a highly competitive space with overlapping intellectual property, requiring careful patent clearance and possible licensing considerations.

Q5: Should companies consider licensing RE41393?
If their products involve the protected features, licensing may reduce legal risk; if not, designing around the claims is advisable.


References

  1. U.S. Patent RE41393, "Method for Generating an Audio-Visual User Interface," Apple Inc., 2013.
  2. U.S. Patent 6,228,177, "Method and Apparatus for Multimedia Interface Generation," Apple Inc., 2001.
  3. U.S. Patent 6,123,259, " Multimedia Control Apparatus," Apple Inc., 2000.
  4. U.S. Patent 6,456,350, "Synchronization of Audio and Video Data," Sony, 2002.
  5. IEEE "Multimedia Synchronization Techniques," IEEE Multimedia, 2003.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent RE41393

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE41393

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Bulgaria 108075 ⤷  Start Trial
Brazil 0207487 ⤷  Start Trial
Canada 2438610 ⤷  Start Trial
China 1774253 ⤷  Start Trial
Estonia 200300396 ⤷  Start Trial
European Patent Office 1385529 ⤷  Start Trial
Hungary 0303175 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.